Bio-Works strengthens the management with Mats Johnson as new CEO
August 1, 2017 / erik abrahamsson
“2017 has so far been a very good year for Bio-Works with growing sales to customers in Europe and a new strategic investor who will open up the very fast growing market for biosimilar production in South Korea for us. I look very much forward to accelerate the growth of Bio-Works in the life science segment. It is clear that the present growth of Bio-Works comes from sales of our high performance products to key customers in the life science industry. ”, says Mats Johnson, new CEO for Bio-Works.
Mats Johnson has previously been CEO of SweTree Technologies, where he served for over 10 years and took them from early start-up to profitability. Prior to that, he served during 18 years in various commercial and strategic leadership roles with Pharmacia Biotech and other predecessors to GE Life Sciences. He has a good insight and understanding of Bio-Works’ business, its product mix and customer need.
“The board wants with these changes strengthen The Company for our important strategic steps the next coming years with the focus on accelerated sales and the planned IPO at the end of 2017. At the same time we thank Kris for his diligent work in changing and building The Company during his period as CEO”, says Thomas Pollare, new chairman of the board.
For more information, please contact
Mats Johnson, VD, Bio-Works Technologies AB
Mobile: +46 705 165337
Bio-Works, founded 2006 and based in Uppsala, Sweden, designs, develops, manufactures and supplies innovative agarose separation products for the Life Science and Food & Beverage industries. The Bio-Works team has extensive experience in the biotech industry and expertise in developing high performance separation and chromatography media. Our knowledge and capabilities in the life science and food & beverage areas have resulted in a strong product portfolio serving high performance research applications, as well as commercial production requiring high purity and high yield. Our strategic focus is to grow rapidly and profitably in the space of “separation of biomolecules”, notably proteins and peptides, where there are large addressable markets and healthy growth.